Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.

Tytuł:
Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Autorzy:
Wendel S; Hospital Sírio-Libanês Blood Bank, São Paulo, Brazil.
Kutner JM; Hospital Israelita Albert Einstein Blood Bank, São Paulo, Brazil.
Machado R; Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.
Fontão-Wendel R; Hospital Sírio-Libanês Blood Bank, São Paulo, Brazil.
Bub C; Hospital Israelita Albert Einstein Blood Bank, São Paulo, Brazil.
Fachini R; Hospital Sírio-Libanês Blood Bank, São Paulo, Brazil.
Yokoyama A; Hospital Israelita Albert Einstein Blood Bank, São Paulo, Brazil.
Candelaria G; Hospital Sírio-Libanês Blood Bank, São Paulo, Brazil.
Sakashita A; Hospital Israelita Albert Einstein Blood Bank, São Paulo, Brazil.
Achkar R; Hospital Sírio-Libanês Blood Bank, São Paulo, Brazil.
Hamerschlak N; Hospital Israelita Albert Einstein Blood Bank, São Paulo, Brazil.
Scuracchio P; Hospital Sírio-Libanês Blood Bank, São Paulo, Brazil.
Amaral M; Hospital Sírio-Libanês Blood Bank, São Paulo, Brazil.
Dal Ben M; Hospital Sírio-Libanês, São Paulo, Brazil.
Araujo D; Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.
Soares C; Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.
Camargo A; Hospital Sírio-Libanês, São Paulo, Brazil.
Kallás E; Infectious Disease Department, University of São Paulo Medical School, São Paulo, Brazil.
Durigon E; Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.
Reis LF; Hospital Sírio-Libanês, São Paulo, Brazil.
Rizzo LV; Albert Einstein Jewish Institute for Education and Research, São Paulo, Brazil.
Źródło:
Transfusion [Transfusion] 2020 Dec; Vol. 60 (12), pp. 2938-2951. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Arlington, Va. : American Association Of Blood Banks
MeSH Terms:
COVID-19 Serological Testing*
Convalescence*
Antibodies, Neutralizing/*blood
Antibodies, Viral/*blood
COVID-19/*blood
COVID-19/*therapy
Donor Selection/*statistics & numerical data
SARS-CoV-2/*immunology
Adult ; Blood Donors ; Brazil/epidemiology ; COVID-19/immunology ; COVID-19 Nucleic Acid Testing ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Immunization, Passive ; Immunoglobulin A/blood ; Immunoglobulin G/blood ; Immunoglobulin M/blood ; Male ; Middle Aged ; Reverse Transcriptase Polymerase Chain Reaction ; SARS-CoV-2/isolation & purification ; Time Factors ; Young Adult ; COVID-19 Serotherapy
References:
Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387)
Cochrane Database Syst Rev. 2020 May 14;5:CD013600. (PMID: 32406927)
Viruses. 2019 Aug 13;11(8):. (PMID: 31412572)
Chest. 2020 Jul;158(1):e9-e13. (PMID: 32243945)
J Clin Invest. 2020 Apr 1;130(4):1545-1548. (PMID: 32167489)
J Infect. 2020 Aug;81(2):318-356. (PMID: 32283147)
Mucosal Immunol. 2012 Nov;5(6):712-9. (PMID: 22739233)
Vox Sang. 2020 Nov;115(8):601-602. (PMID: 32240537)
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. (PMID: 32221519)
JAMA. 2020 Apr 7;323(13):1239-1242. (PMID: 32091533)
Nature. 2020 Aug;584(7821):437-442. (PMID: 32555388)
Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877)
Vox Sang. 2020 Aug;115(6):495-501. (PMID: 32311760)
Int J Infect Dis. 2020 May;94:49-52. (PMID: 32251798)
Vox Sang. 2020 Aug;115(6):485-487. (PMID: 32319102)
Vox Sang. 2021 Jan;116(1):13-14. (PMID: 32464700)
J Clin Invest. 2020 Sep 1;130(9):4791-4797. (PMID: 32525844)
Mil Med Res. 2020 Mar 13;7(1):11. (PMID: 32169119)
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6. (PMID: 15616839)
Emerg Infect Dis. 2020 Jul;26(7):1631-1633. (PMID: 32243255)
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9. (PMID: 33221383)
Nat Med. 2020 Aug;26(8):1200-1204. (PMID: 32555424)
Cell. 2020 Jun 25;181(7):1489-1501.e15. (PMID: 32473127)
Pediatr Infect Dis J. 2020 Jul;39(7):e161. (PMID: 32384396)
Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
J Med Virol. 2005 Oct;77(2):147-50. (PMID: 16121363)
Transfusion. 2020 Dec;60(12):2938-2951. (PMID: 32935877)
J Infect Dis. 2015 Jan 1;211(1):80-90. (PMID: 25030060)
Emerg Infect Dis. 2004 Dec;10(12):2244-8. (PMID: 15663874)
N Engl J Med. 2016 Sep 22;375(12):1202-4. (PMID: 27653589)
Trends Immunol. 2020 May;41(5):355-359. (PMID: 32249063)
JAMA. 2020 Apr 28;323(16):1582-1589. (PMID: 32219428)
Transfusion. 2020 Jun;60(6):1332-1333. (PMID: 32374890)
Virus Res. 2014 Dec 19;194:175-83. (PMID: 24670324)
Int J Biol Sci. 2020 Mar 15;16(10):1718-1723. (PMID: 32226289)
Nat Biotechnol. 2020 Sep;38(9):1073-1078. (PMID: 32704169)
PLoS One. 2012;7(11):e50366. (PMID: 23185609)
J Med Virol. 2020 Nov;92(11):2286-2287. (PMID: 32347980)
N Engl J Med. 2007 Sep 13;357(11):1162-3. (PMID: 17855683)
J Infect. 2017 Mar;74(3):302-309. (PMID: 27867062)
Am J Med. 1966 Feb;40(2):217-30. (PMID: 4159195)
Mem Inst Oswaldo Cruz. 2020 Oct 23;115:e200342. (PMID: 33111751)
Emerg Infect Dis. 2016 Sep;22(9):1554-61. (PMID: 27532807)
J Med Virol. 2020 Sep;92(9):1681-1683. (PMID: 32330293)
Lancet Diabetes Endocrinol. 2020 Jul;8(7):562-564. (PMID: 32437642)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Vox Sang. 2020 Oct;115(7):545-547. (PMID: 32240549)
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. (PMID: 32253318)
J Virol. 2002 Nov;76(21):10972-9. (PMID: 12368340)
J Infect Dis. 1999 Feb;179 Suppl 1:S18-23. (PMID: 9988160)
Vox Sang. 2021 Jan;116(1):18-35. (PMID: 32533868)
Lancet Infect Dis. 2020 May;20(5):565-574. (PMID: 32213337)
Transfusion. 2020 Jun;60(6):1123-1127. (PMID: 32374891)
Crit Care Med. 2010 Apr;38(4 Suppl):e66-73. (PMID: 20154602)
Transfusion. 2020 Jun;60(6):1319-1331. (PMID: 32333396)
Transfusion. 2020 Jul;60(7):1643-1644. (PMID: 32428966)
JAMA. 2020 Aug 4;324(5):460-470. (PMID: 32492084)
Lancet. 2020 May 16;395(10236):1544-1545. (PMID: 32380044)
JAMA. 2020 May 12;323(18):1843-1844. (PMID: 32159775)
Transfus Med Rev. 2020 Jul;34(3):141-144. (PMID: 32359789)
PLoS One. 2006 Dec 20;1:e24. (PMID: 17183651)
J Infect Dis. 2004 Jul 15;190(2):373-8. (PMID: 15216475)
Nat Rev Immunol. 2020 Jun;20(6):363-374. (PMID: 32346093)
Virol J. 2018 Dec 27;15(1):192. (PMID: 30587193)
Am J Dis Child (1911). 1946 Jan;71:1-13. (PMID: 21018124)
JAMA. 2020 Aug 4;324(5):455-457. (PMID: 32492105)
JAMA. 2020 Apr 28;323(16):1561-1562. (PMID: 32219429)
Contributed Indexing:
Keywords: COVID-19; SARS-COV-2; coronavirus; convalescent plasma therapy; passive immune therapy
Substance Nomenclature:
0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (Immunoglobulin A)
0 (Immunoglobulin G)
0 (Immunoglobulin M)
Entry Date(s):
Date Created: 20200916 Date Completed: 20201224 Latest Revision: 20231110
Update Code:
20240104
PubMed Central ID:
PMC7756544
DOI:
10.1111/trf.16065
PMID:
32935877
Czasopismo naukowe
Background: Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients.
Methods and Materials: Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence of symptoms for ≥14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus-1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT-PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect-based virus neutralization test neutralizing antibody) and anti-nucleocapsid protein SARS-CoV-2 IgM, IgG, and IgA enzyme-linked immunosorbent assays.
Results: Among 271 donors (41 females, 230 males), 250 presented with neutralizing antibodies. Final RT-PCR was negative on swab (77.0%) or blood (88.4%; P = .46). Final definition of RT-PCR was only defined at more than 28 days after full recovery in 59 of 174 (33.9%) RT-PCR -ve, and 25/69 RT-PCR +ve (36.2%; 13 between 35 and 48 days). Neutralizing antibody titers of 160 or greater were found in 63.6%. Correlation between IgG signal/cutoff of 5.0 or greater and neutralizing antibody of 160 or greater was 82.4%. Combination of final RT-PCR -ve with neutralizing antibody ≥160 was 41.3% (112/271). Serial plasma collection showed decline in neutralizing antibody titers and IgA levels (P < .05), probably denoting a "golden period" for CCP collection (≤28 days after joining the program); IgA might have an important role as neutralizing antibody. Donor's weight, days between disease onset and serial plasma collection, and IgG and IgM levels are important predictors for neutralizing antibody titer.
Conclusions: RT-PCR +ve cases are still detected in 36.2% within 28 to 48 days after recovery. High anti-nucleocapsid protein IgG levels may be used as a surrogate marker to neutralizing antibody.
(© 2020 The Authors. Transfusion published by Wiley Periodicals LLC. on behalf of AABB.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies